Author/Authors :
Rebeiz، نويسنده , , Abdallah G. and Dery، نويسنده , , Jean-Pierre and Tsiatis، نويسنده , , Anastasios A. and OʹShea، نويسنده , , J. Conor and Johnson، نويسنده , , Brent A. and Hellkamp، نويسنده , , Anne S. and Pieper، نويسنده , , Karen S. and Gilchrist، نويسنده , , Ian C. and Slater، نويسنده , , James and Muhlestein، نويسنده , , J. Brent and Joseph، نويسنده , , Diane and Kitt، نويسنده , , Michael، نويسنده ,
Abstract :
Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.
